The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
A unifying model for mTORC1-mediated regulation of mRNA translation
Thoreen, C. C., Chantranupong, L., Keys, H. R., Wang, T., Gray, N. S., & Sabatini, D. M. (2012) · Nature · doi:10.1038/nature11083 · Cited by 1,477
Ingolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M., & Weissman, J. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.086 · Cited by 1,259
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
Translational control in cancer
Silvera, D., Formenti, S. C., & Schneider, R. J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2824 · Cited by 821
Pratilas, C. A., Taylor, B. S., Ye, Q., Viale, A., Sander, C., Solit, D. B., & Rosen, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900780106 · Cited by 614
Tumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585
Moerke, N. J., Aktas, H., Chen, H., Cantel, S., Reibarkh, M. Y., Fahmy, A., Gross, J. D., Degterev, A., Yuan, J., Chorev, M., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.046 · Cited by 572
Montero-Conde, C., Ruiz-Llorente, S., Dominguez, J. M., Knauf, J. A., Viale, A., Sherman, E. J., Ryder, M., Ghossein, R. A., Rosen, N., & Fagin, J. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0531 · Cited by 382
Bordeleau, M.-E., Robert, F., Gerard, B., Lindqvist, L., Chen, S. M. H., Wendel, H.-G., Brem, B., Greger, H., Lowe, S. W., Porco, J. A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34753 · Cited by 332
The biological and therapeutic relevance of mRNA translation in cancer
Blagden, S. P., & Willis, A. E. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.16 · Cited by 176
Evidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A–RNA Complex
Sadlish, H., Galicia-Vázquez, G., PARIS, C. G., Aust, T., Bhullar, B., Chang, L., Helliwell, S. B., Hoepfner, D., Knapp, B., Riedl, R., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400158t · Cited by 127
Thuaud, F., Bernard, Y., Türkeri, G., Dirr, R., Aubert, G., Cresteil, T., Baguet, A., Tomasetto, C., Svitkin, Y. V., Sonenberg, N., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900365v · Cited by 125
Self-citationChallenging resistance mechanisms to therapies for metastatic melanoma
Tentori, L., Lacal, P. M., & Graziani, G. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.10.003 · Cited by 115
Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors
Liu, T., Nair, S. J., Lescarbeau, A., Belani, J. D., Peluso, S., Conley, J., Tillotson, B. P., O’Hearn, P. J., Smith, S. A., Slocum, K. L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3011542 · Cited by 86
Gupta, S. V., Sass, E. J., Davis, M. E., Edwards, R. B., Lozanski, G., Heerema, N. A., Lehman, A., Zhang, X., Jarjoura, D., Byrd, J. C., et al. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9276-7 · Cited by 81
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
Shao, Y., & Aplin, A. E. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.94 · Cited by 76
Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma
Packer, L., East, P., Reis-Filho, J. S., & Marais, R. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00618.x · Cited by 72
Cencic, R., Carrier, M., Trnkus, A., Porco, J. A. J., Minden, M. D., & Pelletier, J. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.07.043 · Cited by 62
Oikonomou, E., Koc, M., Horova, V., Anděra, L., & Pintzas, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021632 · Cited by 40
Inhibitors of Translation Targeting Eukaryotic Translation Initiation Factor 4A
Cencic, R., Galicia-Vázquez, G., & Pelletier, J. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-396546-2.00020-6 · Cited by 24
Cited by
Compromised MAPK signaling in human diseases: an update
Kim, E. K., & Choi, E.-J. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1472-2 · Cited by 1,020
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
New frontiers in translational control of the cancer genome
Truitt, M. L., & Ruggero, D. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.27 · Cited by 378
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367
Metadata
- Authors
- Boussemart, L., Malka-Mahieu, H., Girault, I., Allard, D., Hemmingsson, O., Tomasic, G., Thomas, M., Basmadjian, C., Ribeiro, N., Thuaud, F., Mateus, C., Routier, E., Kamsu-Kom, N., Agoussi, S., Eggermont, A. M., Désaubry, L., Robert, C., & Vagner, S.
- Venue
- Nature
- Published
- 2014-07-27
- Volume
- 513
- Issue
- 7516
- Pages
- 105-109
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2031134972
- Cited by
- 371
- References
- 21
- FWCI
- 16.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.